RELATIVITY1093: This study is recruiting people with stage IV or recurrent non-squamous non-small cell lung cancer to compare the effectiveness of two immunotherapy and chemotherapy treatment combinationsA Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression of 1% to 49%

Exclusion

• Participants must not have epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) translocations, ROS-1 translocations and known BRAFV600E, that are sensitive to available targeted inhibitor therapy; participants with known activating rearranged during transfection (RET) mutations and neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations.
• Participants must not have untreated central nervous system (CNS) metastases.
• Participants must not have concurrent malignancy requiring treatment or history of prior malignancy active within 2 years prior to randomization.
• Participants must not have an active autoimmune disease.
• Participants must not have history of interstitial lung disease or pneumonitis that required oral or intravenous (IV) glucocorticoids.
• Participants must not have a history of myocarditis, regardless of etiology.
• Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.
• Other protocol-defined Inclusion/Exclusion criteria apply.